Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TSPO | P30536 | 2/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696635 | 0.91 | BRD4 (0.53) | ALDH1A1HTTPOLBTSPOPLA2G2A | |
| SCHEMBL11221634 | 0.87 | ALDH1A1 (0.66) | ALDH1A1HTTPOLBTSPOPLA2G2A | |
| SCHEMBL4696393 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HTTPOLBTBXA2R | |
| SCHEMBL4697825 | 0.83 | ALDH1A1 (0.55) | ALDH1A1HTTPOLBTBXA2RMAPT | |
| SCHEMBL4696644 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HTTPOLBTBXA2RSMN1; SMN2 | |
| SCHEMBL4695473 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HTTPOLBALOX5APTBXA2R | |
| SCHEMBL4697527 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HTTPOLBALOX5APTBXA2R | |
| SCHEMBL6047832 | 0.76 | ALDH1A1 (0.45) | ALDH1A1POLBTSPOMAPT | |
| SCHEMBL6047778 | 0.76 | LMNA (0.51) | HTTTP53MAPT | |
| SCHEMBL6047783 | 0.75 | CNR2 (0.46) | ALDH1A1POLBTSPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| EP-1646614-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
| EP-1646614-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005002520-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | ALDH1A1 2026/4885HTT 190/4885POLB 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.